TILMICOSIN
Chemistry - A semi-synthetic macrolide antibiotic, tilmicosin phosphate is commercially available in a 300 mg/ml (of tilmicosin base) injection with 25% propylene glycol.
Pasturella haemolytica are sensitive.
Uses, Indications - Tilmicosin is indicated fort the treatment of bovine respiratory diseases (BRD)caused by Pasturella haemolytica.
Safe use in pregnant animals or in animals to be used for breeding purposes has not beendemonstrated.
Avoid contact with eyes.
Overdosage, Acute Toxicity - The cardiovascular system is apparently the target of toxicity inanimals. In cattle, doses up to 50 mg/kg did not cause death, but SQ doses of 150 mg/kg did causefatalities. Doses as low as 10 mg/kg in swine caused increased respiration, emesis and seizures; 20mg/kg caused deaths in most animals tested. In monkeys, 10 mg/kg administered once caused nosigns of toxicity, but 20 mg/kg caused vomiting and 30 mg/kg caused death.
In cases of human injection, contact physician immediately. The manufacturer has emergencytelephone numbers to assist in dealing with exposure: 1-800-722-0987 or 1-317-276-2000.
Storage, Stability, Compatibility
Store the injection at or below room temperature. Avoid exposure to direct sunlight.Pharmacology - TILMICOSIN
Like other macrolides, tilmicosin has activity primarily against gram positivebacteria, although some gram negative bacteria are affected and the drug reportedly has someactivity against mycoplasma. Preliminary studies have shown that 95% of studied isolates ofPasturella haemolytica are sensitive.
Uses, Indications - Tilmicosin is indicated fort the treatment of bovine respiratory diseases (BRD)caused by Pasturella haemolytica.
Pharmacokinetics - TILMICOSIN
Tilmicosin apparently concentrates in lung tissue. At 3 days post injection, the lung:serum ratio is about 60:1. MIC95 concentrations (3.12 micrograms/ml) for P. Haemolytica persist for a minimum of 3 days after a single injection.Contraindications, Precautions, Reproductive Safety
Not to be used in automatically poweredsyringes or to be given intravenously as fatalities may result. Tilmicosin has been shown to be fatalin swine, non-human primates and potentially fatal in horses.Safe use in pregnant animals or in animals to be used for breeding purposes has not beendemonstrated.
Adverse Effects, Warnings
If administered IM, a local tissue reaction may occur resulting intrim loss. Edema may be noted at the site of subcutaneous injection.Avoid contact with eyes.
Overdosage, Acute Toxicity - The cardiovascular system is apparently the target of toxicity inanimals. In cattle, doses up to 50 mg/kg did not cause death, but SQ doses of 150 mg/kg did causefatalities. Doses as low as 10 mg/kg in swine caused increased respiration, emesis and seizures; 20mg/kg caused deaths in most animals tested. In monkeys, 10 mg/kg administered once caused nosigns of toxicity, but 20 mg/kg caused vomiting and 30 mg/kg caused death.
In cases of human injection, contact physician immediately. The manufacturer has emergencytelephone numbers to assist in dealing with exposure: 1-800-722-0987 or 1-317-276-2000.